Refine by
Metabolic Disorder Articles & Analysis
51 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
"This groundbreaking synthetic peptide has the potential to transform the way we manage this complex metabolic disorder, providing patients with a more comprehensive and effective approach to improving their overall health and well-being." ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders. Mitochondrial diseases are a complex and heterogeneous group of disorders caused by mutations in mitochondrial DNA (mtDNA) or nuclear genes that encode proteins involved in mitochondrial function. The ...
” “We’re excited about the progress of our INV-202 program that represents a novel, orally administered option for treating metabolic conditions,” said François Ravenelle, PhD, Chief Executive Officer at Inversago. ...
The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational chemistry, biology, medicinal chemistry, and clinical development, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation ...
INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. ...
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding Company to Introduce Product at IFSO 2022 World Congress in August; Sales to Commence in September ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions ...
Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the insulin producing pancreatic β-cells, is ...
About ASC Therapeutics ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in vivo gene editing and allogeneic cell therapies for hematological, metabolic, and other rare diseases. Led by a management team of industry veterans with significant global experience in gene and cell therapy, ASC Therapeutics is developing multiple ...
” About ASC Therapeutics ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in-vivo gene editing and allogeneic cell therapies for hematological, metabolic, and other rare diseases. Led by a management team of industry veterans with substantial global experience in gene and cell therapy, ASC Therapeutics is developing ...
As compared to MSUD patients, MSUD calves exhibit a similar phenotype and are closely matched for size and metabolic rate. Without treatment they exhibit cerebral edema by day of life 3 and die soon after. ...
The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits. About STZ Model In this treatment model of diabetic kidney disease, mice were allowed to develop complication of diabetes for twelve weeks after STZ injection. ...
About ASC Therapeutics ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in-vivo gene editing and allogeneic cell therapies for hematological, metabolic, and other rare diseases. Led by a management team of industry veterans with significant global experience in gene and cell therapy, ASC Therapeutics is developing multiple ...
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic, metabolic, and other rare diseases has received from the United States (U.S.) ...
Gene therapy drugs are in clinical trials with demonstrated efficacy in ophthalmology, neurological disorders, muscular tissue disorders, hematological disorders, metabolic disorders, and oncological diseases. ...
The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable ...
Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology. In 2022, the company is opening technological hubs in Boston, USA, and Kobe, Japan, to ...
Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders and immuno-oncology. The company is currently opening technological hubs in Boston, USA, and Kobe, Japan, to ...
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S. ...